MAP2K7 and non-small cell lung carcinoma: Recently, early clinical evidence from clinical studies of MK-2206 used in combination with targeted therapy or chemotherapy has been reported [16, 17], and a clinical study including the combination of MK-2206 with a MEK inhibitor is presently ongoing in patients with advanced non-small-cell lung cancer (NSCLC) [18].